bilaterals.org logo
bilaterals.org logo

Intellectual property

Even before the World Trade Organization (WTO) lurched into its current state of crisis, bilateral FTAs had become a tool of choice for corporate and state interests seeking to expand intellectual property rights (IPR) standards. IPRs confer monopoly rights over intangible goods and services — methods of doing business on the internet, trademarks, computer programmes, designs, manufacturing processes, drug formulations or types of rice. They give IPR owners the right to prevent anyone from making or using their "creation". As such, they provide companies a direct tool to control a portion of the market, to block out competition and to fence off territories. Ironically, while IPR chapters are key aspects of many “free” trade and investment agreements, they are little more than protectionism for transnational corporations (TNCs), administered by governments. TNCs argue that without monopolies, there will be no innovation. Sharing should be banned; only capitalistic trade based on exclusive private property should be the norm.

Through FTAs, bilateral investment treaties (BITs) and other forms of direct agreements between countries, the US and Europe are insisting that the partner country adopt their standards of IPR protection and enforcement. This process has happened multilaterally via the WTO and the World Intellectual Property Organization. But it is now being pushed very aggressively through unilateral, bilateral and regional agreements — deals which go much further than the WTO’s Agreement on Trade-Related aspects of Intellectual Property rights (TRIPs). FTAs are setting “TRIPs-plus” standards.

The US imposes patents on plants and animals in its FTAs, while the EU and Japan, for the benefit of their biotech companies, push the UPOV Convention, a set of patent-like rules to prevent farmers from saving seeds. Meanwhile, pharmaceutical corporations have turned to FTAs as tools to impose stricter rules preventing the manufacture and trade of generic drugs. For many countries, and many peoples, these propositions are nothing short of revolutionary. Because it means they have to

 extend protection for branded drugs and limit parallel imports, hampering the availability of affordable generic medicines
 start patenting plants and animals, which means farmers cannot save seed or reproduce fish breeds or livestock
 get rid of screen quotas that give preference to the showing of local films
 start patenting computer software, to the detriment of local programmers and the creative open source movements now mushrooming up across the world as a cheaper alternative to Microsoft
 extend copyright protection, which already causes serious problems for students, libraries and educational institutions
 clamp down on piracy of popular consumer goods like digital products, clothing and music
 make IPR infringements criminal offences, even though IPR is part of civil law
and the list goes on.

Through IPRs, corporations seek monopoly control over vast areas of life. They expect that we should all regularly pay them licenses to use their products and to reimburse their research and development costs. Never mind all the public subsidies, tax breaks, university contract labour and so on that go into their research and development in the first place. IPR laws being pushed through bilateral channels make it public policy that countries should protect the TNCs, the real pirates.

Because of the serious implications that ‘TRIPs-plus’ IPR chapters of FTAs have for broad cross-sections of societies, in some anti-FTA struggles, such as the fightback against the US-Thailand FTA, farmers and people living with HIV/AIDS have joined together in their opposition of this new threat to their survival. Concerns have also been raised about the way in which the EU’s EPAs include TRIPs-plus provisions, while Indigenous Peoples in many countries continue to assert alternative frameworks for the use and sharing of traditional knowledge that challenge the capitalist, commodified logic of “intellectual property rights” enshrined in free trade and investment agreements.

More recently, a new development in transnational IPR enforcement has sparked opposition and controversy, including major protests in many European cities. In October 2011, after a secretive negotiations process, the Anti-Counterfeiting Trade Agreement (ACTA) was signed by a number of countries and will come into effect once six countries have ratified it. ACTA would potentially set up a new international legal framework for enforcing IPR. Opponents have criticized the agreement’s impact on privacy, freedom of expression and internet freedoms, and generic drug manufacturing.

last update: May 2012

Photo: Chile Mejor Sin TLC


Aussie BitTorrent case to test Aust-US FTA
Warner Music Australia and other record companies are suing ISP Swiftel Communications for copyright infringement for allegedly hosting and maintaining two Internet computer servers and a Web site called Archie’s Hub which deploys the BitTorrent application. The case is the first to test legislation passed to enact the Australian-United States Free Trade Agreement.
Drug deal gone bad
A group of US companies, represented by the Pharmaceutical Research and Manufacturers of America (PhRMA), has expressed concern regarding approval by the Egyptian Ministry of Health for some 500 generic versions of patented drugs.
A world united? The US approach to the protection of regulatory data
The US has been using Free Trade Agreements to push a US-style system for data exclusivity.
IPR: Deprive Doha of all substance
How through bilateral agreements EFTA states restrict access to medicines
IPR: “TRIPS-plus” through EFTA’s back door (updated)
How Free Trade Agreements concluded with EFTA-States impose much stronger rules on Developing Countries for IPRs on life than the WTO
EU takes piracy fight to non-EU countries
The European Commission yesterday launched a new campaign to tackle IPR deficiencies in countries outside the European Union.
Bilateral agreements and a TRIPS-plus world: the Chile-US FTA
In these issues papers, the author examines a subject of importance in the developing international intellectual property regime and highlights the key issues arising. The topics have been chosen following consultations with negotiators from developing countries and respond to their concerns.
EU demands improved intellectual property protection from Israel
The European Commission has decided to increase pressure on Israel to adopt more stringent intellectual property protection for the benefit of EU pharmaceutical companies.
Farmers risk violating US patents
Thai farmers risk being held liable for patent violations under patent application rights for genetically modified (GM) papaya being considered by American biotechnologists working with Thai scientists, experts said yesterday.
The work of USTR on intellectual property
In this work, we consult closely with Congress on our priorities and strategies; we use domestic trade law; regional initiatives in Europe, Asia (APEC), Latin America (FTAA) and Africa; existing institutions, notably the World Trade Organization (WTO) and the World Intellectual Property Organization (WIPO).